REGiMMUNE Corp. Announces Publication of preclinical GvHD data

Tokyo, JAPAN–(Nov 22, 2010) – REGiMMUNE Corp. (“Company”) is pleased to announce the acceptance and publication of the paper entitled “Pharmacological Expansion of Donor-derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute GvHD Lethality without Abrogating GvL in Murine Models.” by the Biology of Blood and Marrow Transplantation(in press), the official publication of the American Society for Blood and Marrow Transplantation. This paper was authored by Drs. Omar Duramad and Reiko Namikawa,

Mr. Haru Morita, President and CEO, commented as follows:

“Acceptance by this highly respected, peer reviewed journal not only permits us to share more of our knowledge of reVax’s novel effects with the scientific community but it is also a meaningful developmental step for RGI-2001, which is being developed for GvHD associated with hematopoietic stem cell transplantation. Importantly, this study demonstrated for the first time that a compound, RGI-2001, expands naturally occurring regulatory T (nTreg) cells to extend survival of animals in in vivo GvHD model. It also reveal that the treatment does not abrogate Graft-versus-Leukemia (GvL) activity which addresses to major issues of existing therapeutics. This fundamental evidence, combined with strong supportive basic science studies, supported initiation of the clinical trial in patients with undergoing hematopoietic stem cell transplantation.”